[The pharmacokinetic and immunopharmacological aspects of prodigiozan interaction with psychotropic agents].
In experiments on white male mice it was found that an immunostimulant prodigiozan suppresses the activity of cytochrome P-450-dependent liver monohygenases that results in modulation of the activity of neuroleptics (aminazine and haloperidol) administered against its background. Their activity is assessed by the "open field "test" and the "tail suspension test". One could observe a delay of the occurrence of the neuroleptics' effect and prolongation of the effect. Acute toxicity of aminazine was shown to decrease. The changes are most probably due to a slowing of metabolism of the neuroleptics in the liver. On the other hand, administration of neuroleptics against the background of prodigiozan fails to affect its immunostimulating effect despite diverse influences of the drugs on the activity of the liver monooxygenase.
Sibiriak
S V
SV
Alekhin
E K
EK
D000276:Adjuvants, Immunologic; D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000633:toxicity; D001522:Behavior, Animal / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D007113:Immunity, Innate / Q000187:drug effects; D007928:Lethal Dose 50; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051379:Mice; D011354:Prodigiozan / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000401:mortality; D011619:Psychotropic Drugs / Q000493:pharmacokinetics* / Q000633:toxicity
D000276:Adjuvants, Immunologic; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D011354:Prodigiozan